Drug Profile
NOV 11
Alternative Names: NOV-11Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator MorphoSys; Novartis
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological disorders
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for phase-I development in Haematological-disorders in Germany
- 28 Jul 2020 NOV 11 is still in phase-I development in Haematological-disorders in Germany (Morphosys pipeline July 2020)
- 27 Jul 2015 Phase-I clinical trials in Haematological disorders in Germany (unspecified route)